STENTYS Expands Marketing of the Self-Apposing Stent in South America
10 July 2014 - 1:45AM
Business Wire
STENTYS (FR0010949404 — STNT), a medical technology company
commercializing the world’s first and only
Self-Apposing® stent to treat acute myocardial
infarction (AMI), today announced its first distribution contracts
in South America.
STENTYS has established distributor agreements in Argentina,
Chile and Colombia. These contracts represent the first step in
STENTYS’ strategy to expand its commercial presence into the Latin
American coronary stent market, which is estimated to be worth over
$200 million.
STENTYS intends to extend its coverage to other countries in
this region, notably Brazil, Mexico and Venezuela, by the end of
2015.
Gonzague Issenmann, Chief Executive Officer and co-founder of
STENTYS, commented: “After recent expansion into the
Middle East in 2013 and Southeast Asia at the beginning of this
year, entering into new distributor relationships in South America
clearly indicates the successful execution of our worldwide growth
strategy. The ramp up in these high-potential emerging markets will
be further supported next year by the commercialization of the
Sirolimus-eluting stent, which should obtain CE Marking during the
second half of 2014.”
- Upcoming financial
publication
STENTYS expects to publish its revenues for the first half of
2014 on July 24, 2014, after market.
About the STENTYS Self-Apposing® Stent
The STENTYS Self-Apposing® Stent addresses the stent-sizing
dilemma that cardiologists are confronted with when treating heart
attack patients or patients with atypical artery anatomy. Its
flexible, self expanding design takes the shape of the patient’s
unique vessel anatomy and apposes to the irregular contours of a
blood vessel, in particular after an AMI as the vessel dilates and
the clot dissolves. It reduces the risk of malapposition and
complications associated with conventional stents in this setting.
The STENTYS Self-Apposing Stent has been marketed in Europe since
receiving CE Mark in 2010. The STENTYS Sirolimus-eluting stent
should receive the CE Mark during the second half of 2014.
About STENTYS
STENTYS is developing and commercializing innovative solutions
for the treatment of patients with acute myocardial infarction
(AMI, or heart attack) and complex coronary artery disease.
STENTYS’ Self-Apposing® Stents are designed to adapt to vessels
with ambiguous or fluctuating diameters, particularly in the
post-infarction phase, in order to prevent the malapposition
problems associated with conventional stents. In the APPOSITION III
clinical trial, STENTYS stents demonstrated a very low one year
mortality rate among 1,000 high-risk AMI patients when compared to
recent studies with conventional stents. More information is
available at www.stentys.com.
This press release contains forward looking statements about the
Company’s business. Such forward looking statements are based on
numerous assumptions regarding the Company’s present and future
business strategies and the environment in which it will operate in
the future which may not be accurate. Such forward-looking
statements involve known and unknown risks which may cause the
Company’s actual results, performance or achievements to differ
materially from any future results, performance or achievements
expressed or implied by such forward-looking statements. Such
factors include, among others, risks associated with the
development and commercialization of the Company’s products, market
acceptance of the Company’s products, its ability to manage growth,
the competitive environment in relation to its business area and
markets, its ability to enforce and protect its patents and
proprietary rights, uncertainties related to the U.S. FDA approval
process, including with respect to a pre-market approval for the
Company’s BMS, slower than expected rates of patient recruitment
for clinical trials, the outcome of clinical trials, and other
factors, including those described in the Section 4 “Risk Factors”
of the Company’s 2011 Registration Document (document de référence)
filed with the French Autorité des Marchés Financiers on August 27,
2013 under number R.13-040 as such section may be updated from time
to time.
STENTYS is listed on Comp. B of the NYSE Euronext ParisISIN:
FR0010949404 – Ticker: STNT
STENTYSStanislas Piot, +33 (0)1 44 53 99
42CFOstan.p@stentys.comorNewCap.Dusan Oresansky / Pierre
Laurent, +33 (0)1 44 71 94 93Financial Communication / Investor
Relationsstentys@newcap.frorUS: MacDougall Biomedical
CommunicationsCharles Liles or Kari Watson,
781-235-3060orHunter Marshall,
650-339-7533stentys@macbiocom.com
Stevia Nutra (CE) (USOTC:STNT)
Historical Stock Chart
From Jun 2024 to Jul 2024
Stevia Nutra (CE) (USOTC:STNT)
Historical Stock Chart
From Jul 2023 to Jul 2024